SecBot SecBot
Insider Cluster (2 insiders) ·Filed May 7, 2026

ATRA

Atara Biotherapeutics, Inc.
MIXED
Impact 5/10
Horizondays Processed6mo ago
Insider cluster: 2 insiders, $7.9M total
Actionable Insight ◆ Mixed

The simultaneous large buy and sell by two major 10% owners creates a split signal. EcoR1's $4.74M purchase is a bullish vote of confidence, but Panacea's $3.17M sale suggests some insiders are taking profits.

DirectionMixed
Confidencemedium
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$9.93
T+0 close · May 6, 2026 · via day close
Latest settled
−13.90%
T+60 · $8.55
Vs SPY
−17.73%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $9.93entry
  2. T+1 · 6mo ago −16.01%α −16.84% · $8.34
  3. T+5 · 6mo ago +5.54%α +4.03% · $10.48
  4. T+20 · 6mo ago −3.02%α −6.16% · $9.63
  5. T+60 · 4mo ago −13.90%α −17.73% · $8.55
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Atara Biotherapeutics saw a mixed insider cluster: 10% owner EcoR1 Capital bought $4.74M worth of shares, while director/10% owner Panacea Innovation sold $3.17M worth on the same day. The net $1.57M buying is modest relative to ATRA's $71M market cap (~2.2%), but the simultaneous insider buying and selling creates a conflicting signal that warrants caution.

Key Financial Metrics

Direction
mixed
Total Value
$1.6M
Insiders
2

Key Facts

  • EcoR1 Capital purchased 507,407 shares at $9.35 for $4.74M on 2026-05-07
  • Panacea Innovation sold 313,446 shares at $10.10 for $3.17M on 2026-05-07
  • Net insider buying of ~$1.57M, representing ~2.2% of ATRA's $71M market cap
  • Both parties are 10% owners; no C-suite insiders traded

Financial Impact

Net insider buying of ~$1.57M, ~2.2% of market cap

market capinsider ownership

Risk Factors

  • Insider selling by a 10% owner may signal lack of confidence in near-term prospects
  • No C-suite participation reduces the signal strength of insider activity

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
70% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-ATRA-1778539528445

Track record

11 reports on ATRA

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 10, 20266d ago S-3 Bearish 5/10 Entry $8.23 to $7.93 Now $6.40 +22.24% ▲ +3.65% +3.29% vs SPY
  2. Nov 10, 20266d ago 8-K Neutral 5/10 Entry $8.23 to $7.93 Now $6.40 −22.24% ▼ −3.65% −3.29% vs SPY
  3. Jun 26, 202620w ago 8-K Neutral 3/10 Entry $11.17 to $11.48 Now $6.40 −42.70% ▲ +2.78% +2.00% vs SPY
  4. Jun 15, 202622w ago 3 Neutral 2/10 Entry $9.62 to $9.67 Now $6.40 −33.47% ▲ +0.52% +1.77% vs SPY
  5. May 7, 202627w ago 8-K Neutral 4/10 Entry $9.93 to $8.34 Now $6.40 −35.55% ▼ −16.01% −16.84% vs SPY
  6. May 7, 202627w ago Insider Cluster Mixed 5/10 Viewing Entry $9.93 to $8.34 Now $6.40 −35.55% ▼ −16.01% −16.84% vs SPY
  7. Apr 24, 202629w ago DEFA14A Neutral 3/10 Entry $4.99 to $4.73 Now $6.40 +28.26% ▼ −5.21% −4.73% vs SPY
  8. Mar 17, 202634w ago S-3 Neutral 4/10 Entry $5.00 to $5.12 Now $6.40 +28.00% ▲ +2.40% +2.67% vs SPY
  9. Mar 12, 202635w ago 8-K Neutral 5/10 Entry $6.90 to $6.50 Now $6.40 −7.25% ▼ −5.80% −5.20% vs SPY
  10. Mar 3, 202636w ago 8-K Mixed 6/10 Entry $5.42 to $5.39 Now $6.40 +18.08% ▼ −0.55% −1.31% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 11, 2026